MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/blood.2023021184

Медицинская библиотека · Blood · 2024

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231.

Hayashi Robert J, Hermiston Michelle L, Wood Brent L, Teachey David T, Devidas Meenakshi, Chen Zhiguo, Annett Robert D, Asselin Barbara L, August Keith, Cho Steve, Dunsmore Kimberly P, Freedman Jason Lawrence, Galardy Paul J, Harker-Murray Paul, Horton Terzah M, Jaju Alok, Lam Allison, Messinger Yoav H, Miles Rodney R, Okada Maki, Patel Samir, Schafer Eric S, Schechter Tal, Shimano Kristin A, Singh Neelam, Steele Amii, Sulis Maria L, Vargas Sarah L, Winter Stuart S, Wood Charlotte, Zweidler-McKay Patrick A, Loh Mignon L, Hunger Stephen P, Raetz Elizabeth A, Bollard Catherine M, Allen Carl E

СтатьяКлиническое исследование III фазыРандомизированное исследованиеМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

Defining prognostic variables in T-lymphoblastic lymphoma (T-LL) remains a challenge. AALL1231 was a Children's Oncology Group phase 3 clinical trial for newly diagnosed patients with T acute lymphoblastic leukemia or T-LL, randomizing children and young adults to a modified augmented Berlin-Frankfurt-Münster backbone to receive standard therapy (arm A) or with addition of bortezomib (arm B). Optional bone marrow samples to assess minimal residual disease (MRD) at the end of induction (EOI) were collected in T-LL analyzed to assess the correlation of MRD at the EOI to event-free survival (EFS). Eighty-six (41%) of the 209 patients with T-LL accrued to this trial submitted samples for MRD assessment. Patients with MRD <0.1% (n = 75) at EOI had a superior 4-year EFS vs those with MRD ≥0.1% (n = 11) (89.0% ± 4.4% vs 63.6% ± 17.2%; P = .025). Overall survival did not significantly differ between the 2 groups. Cox regression for EFS using arm A as a reference demonstrated that MRD EOI ≥0.1% was associated with a greater risk of inferior outcome (hazard ratio, 3.73; 95% confidence interval, 1.12-12.40; P = .032), which was independent of treatment arm assignment. Consideration to incorporate MRD at EOI into future trials will help establish its value in defining risk groups. CT# NCT02112916.

Для цитирования: Hayashi Robert J, Hermiston Michelle L, Wood Brent L, Teachey David T, Devidas Meenakshi, Chen Zhiguo, Annett Robert D, Asselin Barbara L, August Keith, Cho Steve, Dunsmore Kimberly P, Freedman Jason Lawrence, Galardy Paul J, Harker-Murray Paul, Horton Terzah M, Jaju Alok, Lam Allison, Messinger Yoav H, Miles Rodney R, Okada Maki, Patel Samir, Schafer Eric S, Schechter Tal, Shimano Kristin A, Singh Neelam, Steele Amii, Sulis Maria L, Vargas Sarah L, Winter Stuart S, Wood Charlotte, Zweidler-McKay Patrick A, Loh Mignon L, Hunger Stephen P, Raetz Elizabeth A, Bollard Catherine M, Allen Carl E. MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231.. Blood. 2024. DOI: 10.1182/blood.2023021184.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.